Role of molecular and metabolic defects in impaired performance of dystrophic skeletal muscles

Sukhwinder K. Bhullar\textsuperscript{1}, Mohamad Nusier\textsuperscript{2}, Anureet K. Shah\textsuperscript{3}, Naranjan S. Dhalla\textsuperscript{1,*}

\textsuperscript{1}Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtzen Research Centre and Department of Physiology and Pathophysiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R2H 2A6, Canada
\textsuperscript{2}School of Medicine, Jordan University of Science and Technology, Irbid, 3030 Ar-Ramtha, Jordan
\textsuperscript{3}Department of Kinesiology, Nutrition and Food Science, California State University, Los Angeles, CA 90802, USA

*Correspondence: nsdhalia@sbc.ca (Naranjan S. Dhalla)

DOI: 10.31083/j.jmcm0402005

There occurs a progressive weakness and wastage of skeletal muscle in different types of muscular dystrophy. The loss of muscle fibers in dystrophic muscle with impaired function is associated with leakage of intracellular enzymes, maldistribution of electrolyte content and metabolic defects in myocytes. Marked increases in the sarcotubular (SL) Na\textsuperscript{+}-K\textsuperscript{+} ATPase and Ca\textsuperscript{2+}/Mg\textsuperscript{2+}-ecto ATPase activities, as well as depressions in the sarcoplasmic reticulum (SR) Ca\textsuperscript{2+}-uptake and Ca\textsuperscript{2+}-pump ATPase activities were seen in dystrophic muscles of a hamster model of myopathy. In addition, impaired mitochondrial oxidative phosphorylation and decrease in the high energy stores as a consequence of mitochondrial Ca\textsuperscript{2+}-overload were observed in these myopathic hamsters. In some forms of muscular dystrophy, it has been shown that deficiency of dystrophin produces marked alterations in the SL permeability and promotes the occurrence of intracellular Ca\textsuperscript{2+}-overload for inducing metabolic defects, activation of proteases and contractile abnormalities in dystrophic muscle. Increases in SR Ca\textsuperscript{2+}-release channels, SL Na\textsuperscript{+}-Ca\textsuperscript{2+} exchanger and SL store-operated Ca\textsuperscript{2+}-channels have been reported to induce Ca\textsuperscript{2+}-handling abnormalities in a mouse model of muscular dystrophy. Furthermore, alterations in lipid metabolism and development of oxidative stress have been suggested as mechanisms for subcellular reorganization and cellular damage in dystrophic muscle. Although, several therapeutic interventions including gene therapy are available, these treatments neither fully prevent the course of development of muscular disorder nor fully promote the function of dystrophic muscle. Thus, extensive reasearch work with some novel inhibitors of oxidative stress, SL Ca\textsuperscript{2+}-entry processes as well as store-operated Ca\textsuperscript{2+}-channels, Na\textsuperscript{+}-Ca\textsuperscript{2+} exchanger and Ca\textsuperscript{2+}/Mg\textsuperscript{2+}-ecto ATPase (Ca\textsuperscript{2+}-gating mechanism), as well as SR Ca\textsuperscript{2+}-release and Ca\textsuperscript{2+}-pump systems needs to be carried out in combination of gene therapy for improved beneficial effects in muscular dystrophy.

Keywords
Dystrophic muscle, Dystrophin deficiency, Sarcolemmal defects, Sarcoplasmic reticulum Ca\textsuperscript{2+}-handling; Store-operated Ca\textsuperscript{2+}-channels, Mitochondrial Ca\textsuperscript{2+}-overload

1. Introduction

Muscular dystrophy is a deadly genetic disorder which represents a group of complex muscular diseases. Patients with this disease generally suffer from muscle weakness as well as loss of ambulation, and mostly die in their early twenties due to respiratory and cardiac complications [1, 2]. The first historical account of muscular dystrophy was given in 1830s by Conte and Gioja that this disease causes progressive weakness of multiple muscle groups [3]; however, in 1852, Edward Meryon suggested that a disorder in the cell membrane causes muscular dystrophy but the disease was mistaken for tuberculosis [4]. It was suspected that this disease is genetically transmitted by females and it affects males only, in addition to causing progressive muscle damage which is replaced with connective tissue. Furthermore, it was pointed out that the development of this skeletal muscle disorder is not only age and sex dependent but it also affects cardiac muscle in advanced stages [4]. Later on in 1868, this disease was called Duchenne muscular dystrophy (DMD) after the name of a French neurologist, Guillaume Duchenne, due to his significant contributions in understanding its mechanism [5]. Most of the diagnostic criteria of this disorder, established at that time, are still being used and these include: (a) weakness in legs; (b) hyperlordosis; (c) hypertrophy of weak muscle; (d) reduced muscle contractility on electrical stimulation; (e) absence of bladder or bowel dysfunction; and (f) sensory disturbances and febrile illness. In addition, there occurs cardiomyopathy and mental retardation at advanced stages of this disease and results in death at early age. The progressive nature of these characteristics of muscular dystrophy is depicted in Fig. 1 [6–9]. It is pointed out that in 1878, Gowers was the first to report the genetic basis of muscular dystrophy [10] but it was not until 1891, when the concept of histological alterations in muscle was outlined and the classification of muscular dystrophies such as infantile and juvenile types along with many other subtypes was described [11].
Currently, there are approximately 50 muscular dystrophy causative genes and more than 40 types and subtypes of these are associated with genetic mutations. These various forms of muscular dystrophies have been characterized by patterns of their inheritance, symptoms, origin of gene mutation, age at onset, rate of progression and level of severity [12]. The spectrum of mutations varies as it ranges from complete deficiency of a gene product to a decrease in gene expression and/or expression of an abnormal molecule with complete or partial loss of functionality. Most of the major types of muscular dystrophies are categorized on the basis of X-linked, autosomal dominant and autosomal recessive genes; the location of altered gene product lies in muscle fiber but is linked to other proteins, enzymes and extracellular matrix [12–14]. While DMD, Becker muscular dystrophy and Limb-Girdle dystrophies are the common forms of this disease, it is noteworthy that DMD is the most prevalent and severe form among various types of muscular dystrophies. In fact, over 80% of cases of muscular dystrophy worldwide are associated with DMD, whereas most of the other types are fairly rare [12]. The global prevalence of DMD is 19.8 per 100,000 male births [15]. However, there are variations in disease etiology; the common physiognomies of muscular dystrophy include primary genetic defects and mechanisms based on repetitive cycles of muscle degeneration, necrosis and impaired regeneration resulting in muscle fibrosis, muscle wastage and muscle dysfunction [8, 16]. The evaluation of family history and physical symptoms such as contracture, muscle stiffness, and weakness are the basic diagnostic procedures. In addition to mutation screening in the predicted gene, the assessment for muscular dystrophies is carried out from the determination of muscle weakness, serum creatine kinase (CK) levels, muscle biopsy examination, muscle magnetic resonance imaging, neurological evaluation, electromyographic and electrocardiographic analysis as well as exercise tolerance examination [16].

In spite of extensive preclinical and clinical research efforts over the past 50 years, the exact pathogenesis and therapies of muscular dystrophy remain to be poorly understood. It should also be emphasized that muscular dystrophy is not an entity but represents a group of various muscle disorders, which differ from one another with respect to the location of defects in plasma membrane, as well as transmembrane, extracellular matrix, nuclear membrane, nucleus and cytosol proteins. Since clinical phenotype and pathophysiology of muscle degeneration are different in each type of muscular dystrophy, this article is planned to deal with biochemical and metabolic alterations in dystrophic muscles from all forms of this disease in a general way rather than in any specific manner. It is noteworthy that several molecular and biochemical defects have been identified in dystrophic muscle and their modulation has been shown to
slow down the disease progress \[ \cite{12, 17–25} \]. Abnormalities in dystrophic muscle include increased membrane permeability, \( \text{Ca}^{2+} \)-handling defects, depressed energy production, oxidative stress and myocyte necrosis as well as apoptosis. Impairment of the blood flow to skeletal muscle is invariably associated with dystrophic muscle dysfunction. It is also pointed out that irrespective of differences in the pathogenesis of different types of muscular dystrophy, dystrophic muscles from all types of diseased subjects show similar metabolic defects and impaired function. This article is therefore intended to provide a comprehensive and updated information about metabolic and biochemical alterations in dystrophic skeletal muscle during the development of muscular disorder in general. Derangements for abnormal \( \text{Ca}^{2+} \)-entry as well as \( \text{Ca}^{2+} \)-handling in myocytes from dystrophic muscle will also be described in some details and in particular, the role of store-operated \( \text{Ca}^{2+} \)-channels in the development of intracellular \( \text{Ca}^{2+} \)-overload will be outlined. Mechanisms of \( \text{Ca}^{2+} \)-handling abnormalities and metabolic defects in dystrophic muscles from different experimental models of muscular disease will also be described. Some changes in membrane activities and metabolic status of the hind leg muscle from myopathic hamsters will be discussed to show if there is any relationship with impaired muscle performance. Since dystrophin, an important component for anchoring different proteins and enzymes in the membrane, the function of sarcolemma in several forms of muscular dystrophy will be evaluated \[ \cite{13, 14, 20} \]. The significance of dystrophin gene mutations leading to dystrophin deficiency in the development of this disease will also be highlighted. In addition, attempts will be made to describe some of the therapeutic strategies, including gene therapy and pharmacologic interventions, which are used for the management or treatment of muscular disorder.

2. Biochemical defects in dystrophic muscle

Different mechanisms including impaired metabolism \[ \cite{8, 26–31} \], structural and biochemical membrane defects \[ \cite{32–39} \] and \( \text{Ca}^{2+} \) regulatory abnormalities \[ \cite{40–52} \] have been described to understand the pathogenesis of weakness in dystrophic muscle. An increased activity of enzymes, such as CK in the serum is considered to reflect damage to the muscle cell membrane and serves as a sensitive marker for the progression of this disease \[ \cite{53–59} \]. Recent studies with circulating proteins and metabolites have validated different biomarkers for patients with DMD \[ \cite{60–64} \]. It was demonstrated that defects of the plasma membrane lead to leakage of several cellular constituents such as myoglobin, glycogen, potassium, ATP and creatine from muscle fibres in addition to producing increased influx of \( \text{Ca}^{2+} \) in myocytes \[ \cite{33, 43, 65–69} \]. Ultrastructural examination of dystrophic muscle revealed segmental fiber breakdown and \( \text{Ca}^{2+} \)-deposits in myocytes with intact basement membrane as significant features \[ \cite{65, 66, 70–72} \]. Several changes indicating biochemical abnormalities in the sarcolemma (SL) membrane were observed in different types of dystrophic muscle \[ \cite{73–76} \]. Marked alterations in lipid and electrolyte content were also seen in dystrophic muscle indicating abnormal function of the cell for maintaining appropriate levels of intracellular components \[ \cite{73, 77} \]. Thus, it has become evident that the increased permeability of skeletal muscle is reflected by defective SL membrane during the development of muscular disease \[ \cite{43, 70, 78} \].

Alterations in the integrity of dystrophic muscle membrane \[ \cite{79, 80} \] were associated with changes in different SL enzyme systems such as \( \text{Na}^{+} \text{-K}^{+} \) ATPase, \( \text{Ca}^{2+} / \text{Mg}^{2+} \) ecto-ATPase, and adenylyl cyclase \[ \cite{74–76, 81–85} \]. Since both cholesterol and phospholipids are known to exert membrane stabilizing effects \[ \cite{86, 87} \] and the ratio of cholesterol/phospholipids was elevated in dystrophic muscle \[ \cite{88} \], it has been suggested that the observed changes in enzyme activities are a consequence of alterations in the SL lipid composition. Studies from dystrophic muscle fibroblasts and skin fibroblast cultures have also shown different alterations such as cytoplasmic inclusion bodies, defective collagen incorporation as well as membrane defects \[ \cite{89–93} \]. Furthermore, derangements in the function of intracellular membrane systems such as the sarcoplasmic reticulum (SR) \[ \cite{40, 76, 88} \] and mitochondria \[ \cite{41, 76, 94–96} \] were reported in dystrophic muscle. Although no alterations in myofibrillar ATPase activity and contractile proteins in myopathic hamster muscle were observed \[ \cite{30, 76} \], some investigators have shown defective myosin in a chicken model of muscular dystrophy \[ \cite{97} \]. Nonetheless, marked changes in metabolism \[ \cite{26–30, 98} \] indicating the impaired performance of skeletal muscle in different types of muscle disorders may be associated with subcellular defects and metabolic abnormalities. In addition, maldistribution of electrolytes in dystrophic myocytes \[ \cite{66, 77} \], there occurs the development of intracellular \( \text{Ca}^{2+} \)-overload \[ \cite{41–44, 99} \], which activates different proteolytic enzymes \[ \cite{100, 101} \] and leads to muscle breakdown as well as structural defects dystrophic muscle of DMD patients \[ \cite{102, 103} \].

Since the discovery of the DMD gene and identification of the role of dystrophin-deficiency in DMD in 1980s, various genetically engineered animal models have been developed to understand the biology, biochemistry and pathophysiology of different types of muscular dystrophies \[ \cite{104–106} \]. The most widely used is a dystrophin-deficient mouse (mdx), which is considered to be an excellent model for studying DMD \[ \cite{107–115} \]. The other animal models of dystrophin-deficiency have employed pigs \[ \cite{116, 117} \], rats \[ \cite{118, 119} \], dogs \[ \cite{120–122} \] and cats \[ \cite{123, 124} \]. It is pointed out that marked changes in protein, lipids, carbohydrate and energy metabolism have been observed in skeletal muscle from mdx dystrophic mouse \[ \cite{125–129} \]. Furthermore, impaired mitochondrial oxidative phosphorylation and increased \( \text{Ca}^{2+} \) content due to dystrophin-deficiency have been reported in mdx mouse skeletal muscle \[ \cite{130–134} \]. Treatments of mdx dystrophic mouse with \( \text{Ca}^{2+} \)-antagonists, verapamil and diltiazem, as well as with creatine were observed to re-
duce skeletal muscle degeneration and mitochondrial dysfunction [135, 136]. It is noteworthy that skeletal muscle from DMD patients to have also been found to exhibit mitochondrial dysfunction and sarcosomal alterations due to dystrophin-deficiency [137, 138]. It is also pointed out that sarcoglycan-deficiency models have also been developed in different animals such as hamsters, mice and chickens to examine metabolic and cellular defects in various muscular disorders [139–145].

3. Metabolic and subcellular defects in skeletal muscle of myopathic hamster

In order to examine the functional significance of metabolic and subcellular alterations for impaired performance of myopathic muscle, hind leg muscles from two experimental models (BIO 14.6 and UM–X7.1) of Syrian hamster (δ-sarcoglycanopathy) at different stages of development were used [30, 40, 74–76]. It may be noted that the clinical signs of muscle impairment in BIO 14.6 strain of hamsters start developing at the age of 100 to 150 days (early stage) whereas moderate and severe stages of myopathy become apparent at 180–210 days and 260–275 days of age, respectively [30, 146]. On the other hand, UM–X7.1 strain of myopathic hamsters develop degenerative lesions as early as 20 to 30 days whereas these animals at the age of about 60 days and about 150 days were considered to be at moderate and severe stages of muscular disorder, respectively [74, 147]. Although different stages of myopathy in both models of hamsters have been categorized on the basis of pathological lesions in the hind leg, it is understood that these stages are arbitrary and reflect the progression of muscular impairment with respect to the age of animals.

By employing the BIO 14.6 hamster model of myopathy, Sulakhe et al. [74] were the first to show increases in the activities of SL Mg$_2^{2+}$-ATPase and Na$^+$.K$^+$.ATPase in skeletal muscle. This observation showing defect in the SL membrane at the biochemical level was confirmed by Peter and Fiehn [148], who reported increased activities of Na$^+$.K$^+$.ATPase and Ca$^{2+}$.ATPase in myotonic muscles of rats treated with diazacholesterol. Although no changes in skeletal muscle SL ATPase activities were detected at early stages in BIO 14.6 myopathic hamsters, marked increases in the activities of SL Na$^+$.K$^+$.ATPase, Mg$_2^{2+}$-ATPase and Ca$^{2+}$.ATPase were seen in both moderate and severe stages of muscular disorder (Table 1) [75]. Likewise, marked increases in these SL enzyme activities in skeletal muscle were observed in UM–X7.1 strain of myopathic hamsters at both moderate and severe stages except that Na$^+$.K$^+$.ATPase and Mg$_2^{2+}$-ATPase activities were not altered at the moderate stage (Table 1) [76]. Similar increases in the hind leg skeletal muscle SL Na$^+$.K$^+$.ATPase, Mg$_2^{2+}$.ATPase and Ca$^{2+}$.ATPase were seen in rats on vitamin E deficient diet [75], which is considered to be a good model for studying the pathogenesis of muscular weakness [34]. However, preliminary studies with dystrophic skeletal muscles from human showed that SL Na$^+$.K$^+$.ATPase activity was depressed but both Ca$^{2+}$.ATPase and Mg$_2^{2+}$.ATPase activities were increased [75]. Decreased Na$^+$.K$^+$.ATPase and increased Mg$_2^{2+}$.ATPase activities were also observed in SL preparations from dystrophic muscles of Bar Harbor strain of 129/Rej mice [149]. These observations suggest that alterations in SL Na$^+$.K$^+$.ATPase may depend upon the type and stage of muscular disorder; the increased activity of this enzyme may play a compensatory role in maintaining the electrolyte composition of the myopathic muscle whereas the depressed Na$^+$.K$^+$.ATPase may be associated with increased entry of Ca$^{2+}$ through Na$^+$.Ca$^{2+}$ exchange system. Furthermore, the increased activities of skeletal muscle SL Ca$^{2+}$.ATPase and Mg$_2^{2+}$.ATPase, which have been shown to represent Ca$^{2+}$/Mg$_2^{2+}$-ecto ATPase [150], may promote Ca$^{2+}$-influx for the occurrence of intracellular Ca$^{2+}$ overload and thus play a pathogenic role for the impaired performance of myopathic muscle. It is pointed out that SL Ca$^{2+}$/Mg$_2^{2+}$-ecto ATPase, which is activated by millimolar concentrations of Ca$^{2+}$ or Mg$_2^{2+}$, has been suggested to serve as a “gating mechanism” for the entry of Ca$^{2+}$ into the cell [150–153]. Although the status of SL Na$^+$.Ca$^{2+}$-exchange system was not examined in hamster myopathic muscle, the activity of Na$^+$.Ca$^{2+}$-exchange was increased in dystrophic muscle from patients with DMD as well as mdx model of muscular dystrophy in mice [154, 155].

Since the SR plays a critical role in regulating the intracellular Ca$^{2+}$ concentration in myocytes, Ca$^{2+}$.binding and Ca$^{2+}$.transport activities of this subcellular organelle were examined in skeletal muscles of both BIO 14.6 and UM–X7.4 strains of myopathic hamsters at moderate and severe stages of muscular disorder [40, 76]. The results in Table 2 show that ATP-dependent Ca$^{2+}$.binding activities (studied in the absence of oxalate) of SR from skeletal muscles of myopathic animals were not altered at both moderate and severe stages. Although no changes in the ATP-dependent Ca$^{2+}$.uptake activities (studied in the presence of oxalate) of SR of myopathic muscle were detected at moderate stage, these Ca$^{2+}$.transport activities were depressed in both models of myopathy at severe stages. It may also be noted from Table 2 that the SR Ca$^{2+}$.pump ATPase activity was decreased markedly at severe stages of myopathy. Several investigators have also reported defects in the Ca$^{2+}$.transport activities in the SR preparations from different myopathic animals as well as in DMD patients [156–159]. However, others have denied the occurrence of such abnormalities in muscular disorder [160–162], which may be due to the use of skeletal muscles at early or moderate stage of the disease. Thus, it appears that the reduced ability of SR to accumulate Ca$^{2+}$ at the late stage of muscular disease may be secondary to other mechanisms leading to impaired performance of skeletal muscle.

The data in Table 3 show the status of mitochondrial Ca$^{2+}$.binding and Ca$^{2+}$.uptake activities as well as oxidative phosphorylation in UM–X7.1 strain of hamsters at moderate or severe stages of myopathy [76]. No changes in mitochon-
drial Ca$^{2+}$ accumulation and ATPase activities as well as different parameters of oxidative phosphorylation were observed in 150 days old myopathic animals. On the other hand, 60 days old hamster myopathic muscle showed depressions in both mitochondrial Ca$^{2+}$-uptake and oxidative phosphorylation rate, unlike Ca$^{2+}$-binding and ATPase, P:O ratios and RCI values (Table 3). The inability to detect changes in mitochondrial Ca$^{2+}$-transport and oxidative phosphorylation in myopathic muscle at late stages of the disease in UM-X7.1 strain of hamsters was not attributed to the method used for the isolation of mitochondria because the same procedure was employed for obtaining mitochondrial preparation from muscles at moderate stage of muscular disease. Since the mitochondrial defects in myopathic muscle have also been shown to be due to the occurrence of mitochondrial Ca$^{2+}$-overload [41], it is likely that the excessive amount of Ca$^{2+}$ from mitochondria at late stages of myopathy may have been lost during the isolation procedure. Nonetheless, other investigators have shown defects in mitochondrial oxidative phosphorylation activities in myopathic muscles of BIO 14.6 strain of myopathic hamsters [94–96]. Such abnormalities in the mitochondrial oxidative phosphorylation can be seen to impair the ability of myopathic muscle to generate energy for the function of skeletal muscle myocytes. In fact, marked changes in the high energy phosphate content and other metabolic processes showing impaired energy production in skeletal muscles from BIO 14.6 strain of hamsters at late stages of muscular disease have been reported [30]. Some of these data shown in Table 4 indicate that both creatine phosphate and ATP were depressed without any significant changes in ADP and AMP content of dystrophic hamster muscle. Furthermore, lactate, NADH and NADPH were increased indicating marked alterations in muscle metabolism without any changes in pyruvate content of myopathic muscle (Table 4). These observations support the view that...
it is pointed out that more than 1000 mutations have been identified in dystrophin gene. As a part of an incredibly complex group of proteins, dystrophin allows muscle to function properly as well as aids in anchoring various components within muscle cells and link them to the SL membrane [167]. Thus, dystrophin provides a scaffold for holding several molecules in place near the cell membrane whereas dystrophin deficiency dislocates these molecules and cause disorders in their function [167]. There are several reports on structural, functional, biochemical, molecular and metabolic defects, which are induced by these dystrophin gene mutations [13, 29, 73, 170, 171]. Reduction of dystrophinglycoprotein complex promotes the occurrence of structurally unstable SL membrane, which is more permeable to extracellular environment and thus contribute to muscle fiber damage and wastage of skeletal muscles [170, 171]. Particularly, repetitive cycles of contraction and relaxation of dystrophin deficient skeletal muscle produce microtears in the SL membrane, and result in cellular instability and progressive leakage of intracellular components including CK. Such a leakage of CK can be seen to reduce the intracellular level of CK content and thus may impair the storage of energy in skeletal muscle. In addition, the increased permeability of the SL membrane due to dystrophin deficiency will promote an excessive entry of Ca$^{2+}$ into myocytes to result in the development of intracellular Ca$^{2+}$-overload, which is well known to activate different proteolytic enzymes and produce muscle wastage. Furthermore, dystrophin deficiency has been reported to induce different abnormalities in the SL signal transduction pathways, which impair muscle regeneration and induce weakness in muscle performance [171]. A schematic representation of dystrophin deficiency related events is shown in Fig. 2.

It needs to be emphasized that mutations of genes other than for dystrophin gene have also been reported to induce muscular disorders. For example, mutations in dysferlin gene have been shown to decrease dysferlin content and result in progressive development of muscle wasting and myopathic characteristics [172]. Although deficiency of laminin-alpha2, a protein of the extracellular matrix and a component of the

---

**Table 2.** Ca$^{2+}$-transport activities of sarcoplasmic reticulum from skeletal muscles of control and myopathic hamsters of different ages.

|                          | ATP-dependent Ca$^{2+}$- binding (nmoles/mg protein/5 min) | ATP-dependent Ca$^{2+}$ - uptake (µmoles/mg protein/5 min) | Ca$^{2+}$-pump ATPase (µM Pi/mg protein/5 min) |
|--------------------------|------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------|
| A. BIO 14.6 myopathic hamsters |                                                            |                                                           |                                               |
| (i) 220 days old         |                                                            |                                                           |                                               |
| Control                  | 153 ± 22                                                   | 3.6 ± 0.20                                               | −                                             |
| Myopathic (Moderate stage) | 136 ± 11                                                  | 3.4 ± 0.15                                               | −                                             |
| (ii) 260 days old        |                                                            |                                                           |                                               |
| Control                  | 142 ± 5                                                    | 3.8 ± 0.45                                               | 2.76 ± 0.31                                   |
| Myopathic (Late stage)   | 135 ± 7                                                    | 2.3 ± 0.62*                                              | 1.32 ± 0.19*                                 |
| B. UM-X7.1 myopathic hamsters |                                                            |                                                           |                                               |
| (i) 60 days old          |                                                            |                                                           |                                               |
| Control                  | 118 ± 13                                                   | 3.8 ± 0.52                                               | 1.44 ± 0.15                                   |
| Myopathic (Moderate stage) | 95 ± 11                                                    | 3.6 ± 0.21                                               | 1.07 ± 0.19                                   |
| (ii) 150 days old        |                                                            |                                                           |                                               |
| Control                  | 145 ± 12                                                   | 5.2 ± 0.39                                               | 2.56 ± 0.27                                   |
| Myopathic (Late stage)   | 109 ± 14                                                   | 2.8 ± 0.26*                                              | 1.45 ± 0.21*                                 |

The data for BIO 14.6 strain of myopathic hamsters are taken from our paper, Dhalla & Sulakhe. Biochem Med 7, 157–168, 1973 [40] whereas the data for UM-X7.1 myopathic hamsters are taken from our paper Dhalla et al. Clin Sci Mol Med 49, 359–368, 1975 [76].

* Significantly ($P < 0.05$) different from the corresponding control values.

---

**Table 3.** Mitochondrial Ca$^{2+}$-transport and oxidative phosphorylation activities of skeletal muscles from UM-X 7.1 strain of myopathic hamsters of different ages.

|                          | 60 days old | 150 days old |
|--------------------------|-------------|--------------|
| Ca$^{2+}$ - binding (nmoles/5 min/mg) | 84 ± 7      | 79 ± 5       | 116 ± 14 | 113 ± 11 |
| Ca$^{2+}$ - uptakes (nmoles/5 min/mg) | 552 ± 64    | 353 ± 58*    | 596 ± 73 | 571 ± 49 |
| ATPase activity (µmol/5 min/mg)     | 3.9 ± 0.63  | 4.3 ± 0.71*  | 4.5 ± 0.96 | 5.2 ± 0.18 |
| P:O ratio                   | 2.8 ± 0.07  | 2.9 ± 0.05   | 2.9 ± 0.04 | 3.0 ± 0.06 |
| Phosphorylation rate (µmol ADP phosphorylated/min/g protein/min) | 110 ± 8.8  | 81 ± 5.6*    | 127 ± 19.4 | 112 ± 26.0 |
| RCI                         | 5.3 ± 0.52  | 6.3 ± 0.21   | 8.1 ± 1.4 | 7.6 ± 1.1 |

The data are taken from our paper, Dhalla et al. Clin Sci Mol Med 49, 359–368, 1975 [76].

* Significantly ($P < 0.05$) different from the corresponding control values.
Table 4. High energy phosphate stores, glycolytic intermediates and pyridine nucleotides in skeletal muscle of 215 day old BIO 14.6 strain of myopathic hamsters.

|                         | Control     | Myopathic (Late stage) |
|-------------------------|-------------|------------------------|
| (i) Creatine phosphate (µmol/g muscle) | 13.3 ± 0.26 | 6.13 ± 0.49*           |
| (ii) Adenine nucleotides (µmol/g muscle) |             |                        |
| ATP                     | 5.97 ± 0.21 | 4.04 ± 0.27*           |
| ADP                     | 0.35 ± 0.04 | 0.39 ± 0.02            |
| AMP                     | 0.17 ± 0.02 | 0.21 ± 0.02            |
| (iii) Glycolytic intermediates (µmol/g muscle) |             |                        |
| Lactate                 | 1.19 ± 0.02 | 7.18 ± 0.14*           |
| Pyruvate                | 0.050 ± 0.002 | 0.051 ± 0.003     |
| (iv) Pyridine nucleotides (mµmol/g muscle) |             |                        |
| NADH                    | 139 ± 5.0  | 168 ± 3.1*             |
| NADPH                   | 45 ± 3.1   | 67 ± 5.7*              |

The data are taken from our paper, Dhalla et al. Can J Biochem 50, 550–556, 1972 [30].

* Significantly (P < 0.05) different from the corresponding control values.

basal membrane, has also been reported to induce the SL instability and result in the development of muscular disorder [23, 24], dystrophin mutations have been recognized as the primary cause in the development of muscular dystrophy because of a significant decrease in the expression of dystrophin associated complex proteins. In fact, changes in dystrophin associated proteins such as sarcoglycan complex as transmembrane proteins have been shown to promote the production of oxidative stress and lead to muscle cell death as well as stiffness in myopathic muscle [171]. It should be mentioned that neuronal nitric oxide synthase, which interacts indirectly with dystrophin protein, is also influenced markedly due to dystrophin deficiency and thus affects the performance of dystrophic muscle [173]. In addition, some studies have
indicated that the membrane impairment occurs frequently in the absence of dystrophin, leading to localized cell damage and leakage of intracellular constituents [174]. However, a significant increase in total Ca\textsuperscript{2+} content is consistent with excessive Ca\textsuperscript{2+} entry into the cell through damaged membranes due to dystrophin deficiency. Although other pathways of Ca\textsuperscript{2+} entry such as Na\textsuperscript{+}-Ca\textsuperscript{2+} exchange [155] and Ca\textsuperscript{2+}-gating system (Ca\textsuperscript{2+}/Mg\textsuperscript{2+}-ecto-ATPase) [153] may also be enhanced in muscular dystrophy as a consequence of dystrophin deficiency, extensive experiments need to be carried out to make any meaningful conclusion. Nonetheless, it is evident that dystrophin deficiency may play a critical role in the pathogenesis of muscular dystrophy due to the occurrence of intracellular Ca\textsuperscript{2+}-overload [171, 173, 175].

5. Role of store-operated Ca\textsuperscript{2+} entry in muscular dystrophy

The store-operated Ca\textsuperscript{2+} entry (SOCE) is one of the important mechanisms for extracellular Ca\textsuperscript{2+} influx and is activated by depletion of intracellular Ca\textsuperscript{2+} stores [176, 177]. Several studies have been carried out to explore the status of SOCE regulation in normal and dystrophic skeletal muscles [48, 178, 179]. In fact, SOCE was found to play an essential role in some physiological functions including skeletal muscle development, contractile activity and metabolism. Furthermore, it prevents muscle weakness and serves as a signaling pool of Ca\textsuperscript{2+} required to modulate muscle-specific gene expression in myopathic muscle [180–183]. Abnormal increases in the SOCE channel activity result in muscle dysfunction including the activation of Ca\textsuperscript{2+} signaling pathways leading to metabolic disorders, irregular protein handling, and detrimental remodeling phenotype in the pathogenesis of muscular disease [179, 180, 184–186]. The disruption of SOCE channels has been suggested to cause an imbalance in the level of intracellular Ca\textsuperscript{2+} and subsequent Ca\textsuperscript{2+}-dependent activation of proteases and muscle degeneration due to dystrophin deficiency in dystrophic muscle [40, 187, 188]. It has been reported that the occurrence of an excessive SOCE occurrence is an early event in the pathology of muscular dystrophy and the altered Ca\textsuperscript{2+} dynamics in myotubes result in continued cytosolic Ca\textsuperscript{2+} transients and increased Ca\textsuperscript{2+} uptake by mitochondria [187, 189]. The phospholipase A\textsubscript{2} product, lysophosphatidylcholine, was found to trigger Ca\textsuperscript{2+} entry through SL channels, and acts as an intracellular messenger responsible for the opening of store-operated channels in dystrophic fibers [190]. Elevation of intracellular Ca\textsuperscript{2+} was found to increase phospholipase A\textsubscript{2} activity and the overexpression activity of NADPH oxidase and excessive production of reactive oxygen species (ROS) were observed to contribute to the pathology in dystrophin deficient dystrophic muscle [191, 192].

Both STIM1 and Orai1 proteins have been identified as essential components of SOCE channel in the plasma membrane [193, 194]. Studies from genetic mouse models with deletion of these components have provided evidence of impaired skeletal muscle growth, suggesting the physiologic role for SOCE in skeletal muscle development and contractile function [195–199]. These molecular components which skeletal muscle expresses in abundance serve as the main channel constituents involving SOCE for contributing to the mitochondrial Ca\textsuperscript{2+} homeostasis and a range of downstream signaling pathways as well as in the regulation of several transcription factors [144, 200–204]. STIM1 is a multipurpose stress transducer initiated by various stimuli such as oxidation, temperature, hypoxia, and acidification and may regulate varied downstream targets including different ion channels, pumps/exchangers, adaptor proteins, endoplasmic reticulum (ER) chaperones, signaling enzymes, and ER stress/remodeling proteins. On the other hand, Orai1 serves as a SOCE channel in skeletal muscle [205]. Furthermore, fast kinetics of the SOCE activation in the skeletal muscle, depends on the pre-formation of STIM1-protein complexes with the plasma-membrane, whereas Orai1-mediated Ca\textsuperscript{2+} influx appears essential to control the resting Ca\textsuperscript{2+} concentration and proper SR Ca\textsuperscript{2+} filling. Ca\textsuperscript{2+} influx through STIM1-dependent activation of SOCE from the T-tubule system may recycle the extracellular Ca\textsuperscript{2+} loss during muscle stimulation and thereby maintain proper filling of the SR Ca\textsuperscript{2+} stores and muscle function [206, 207]. Various studies have demonstrated that STIM1/Orai1-dependent signals promote muscle fiber maturation, growth, oxidative process, fatigue-resistant fibers, and muscle development [195, 207–209]. There is evidence to suggest that the STIM1/Orai1-dependent SOCE promotes sustained force generation during periods of prolonged activity as well as resistance to muscle fatigue [210–213].

Altered function of essential proteins regulating the SOCE activity, contributes to or amplifies the pathogenesis of muscle disorders including muscular dystrophy. A number of studies have provided evidence for a modulatory contribution of the STIM/Orai1-dependent SOCE in animal models of muscular dystrophy [178, 214–216]. Increased STIM1/Orai1 expression as well as SOCE functionality, including a shift in the threshold for SOCE activation and deactivation to SR luminal Ca\textsuperscript{2+} concentrations have been observed in muscle fibers from dystrophic mice [178, 217]. In another study, although STIM1 levels were unchanged in muscles from dystrophic mice, an increase was found in both Orai1 mRNA and protein levels corresponding to the enhanced SOCE activity and SR Ca\textsuperscript{2+} storage. Since these augmented activities were reduced by either shRNA-mediated Orai1 knockdown or treatment of animals with BTP-2 (a potent CRAC channel inhibitor), it was proposed that increased function of the STIM1/Orai1-dependent SOCE contributes to Ca\textsuperscript{2+}-mediated muscle fiber degeneration in dystrophic mice [218]. Enhanced SOCE and increased muscle inflammation, fibrosis, necrosis, mitochondrial swelling, and serum CK levels, were noticed due to the muscle-specific STIM1 overexpression in dystrophic mice [214]. The role of STIM1-mediated Ca\textsuperscript{2+} signaling for skeletal muscle hy-
pertrophic growth has also been demonstrated in the skeletal muscle STIM1 knockout mice [195]. Furthermore, a correlation of the overstimulation of SOCE in dystrophic cells with increased STIM protein content has been reported [188, 207, 208]. Since overexpression of STIM1 stimulates muscle cell differentiation whereas silencing inhibits this process [208], it is evident that high SOCE and elevated STIM1 levels in muscular dystrophy are associated with greater differentiation of dystrophic myoblasts [198].

Increased rate of SOCE activity with high STIM1 protein levels in dystrophic mice myoblasts has revealed that mutation of dystrophin gene may significantly impact the cellular calcium response to metabolic stimulation. It is pointed out that an aberrant response to extracellular stimuli may contribute to the pathogenesis of muscular dystrophy and inhibition of such responses might modify the progression of this deadly disease [188]. Overactivation of SOCE upon dystrophic cell stimulation may lead to intracellular Ca\(^{2+}\)-overload and increased susceptibility to cell death as well as progressive muscle degeneration [219]. It has been demonstrated that Ca\(^{2+}\)-influx across an unstable SL due to increased activity of the STIM1/Orai1 complex is a major determinant in muscular dystrophy [214] and STIM1/Orai1 along with TRPC1 are involved in increasing SOCE in the dystrophin deficient myotubes in both dystrophic patients and dystrophic mice. Thus, the participation of a specific Ca\(^{2+}\)/PKC/PLC pathway in increasing the SOCE activity may be due to STIM1/Orai1/TRPC1 protein interactions, which are regulated by the dystrophin scaffold [215]. These findings support the functional role of STIM1/Orai1-dependent SOCE in the pathophysiology of muscular dystrophy and are considered to represent a potential therapeutic target [216].

6. Mechanisms of subcellular Ca\(^{2+}\)-handling abnormalities in dystrophic muscle

An excessive amount of Ca\(^{2+}\) entering dystrophic muscle is considered to play a critical role in raising the intracellular level of Ca\(^{2+}\) as well as inducing metabolic defects, subcellular remodeling, Ca\(^{2+}\)-handling abnormalities and impairment of muscular function [15, 20, 25, 47, 155, 171, 180, 185, 217]. Increases in Ca\(^{2+}\)-entry and SL permeability have been shown to be associated with dystrophin deficiency in muscular dystrophy; such defects in some other types of this disease are linked to deficiencies of different proteins including dysferlin and α-sarcoglycan [47, 171, 172, 180, 185, 220]. The role of intracellular Ca\(^{2+}\)-overload in the pathogenesis of muscular disorder is supported by observations that exercise in dystrophic mdx mice enhanced Ca\(^{2+}\)-influx, impaired Ca\(^{2+}\)-homeostasis and aggravated this disease [221]. It should be pointed out that the increased Ca\(^{2+}\)-influx in myopathic muscle may be occurring through SOCE channels [192, 216, 222], voltage-independent Ca\(^{2+}\)-leakage channels [223], voltage-dependent Ca\(^{2+}\)-channels [189] and Na\(^+\)/Ca\(^{2+}\) exchange system [154, 155, 224, 225] in the SL membrane. Since the SL phospholipase A\(_2\) [190] and adenyliclate cyclase activities [226] are increased in dystrophic muscles, these signal transduction systems have also been suggested to participate in enhancing Ca\(^{2+}\)-entry into muscle fiber. The involvement purinoceptor associated mechanisms has also been reported to induce increased Ca\(^{2+}\)-influx because the expressions and activities of P2X receptors are increased in dystrophic muscle [227–229]. The increased activities of both Mg\(^{2+}\)-ATPase and Ca\(^{2+}\)-ATPase in the surface membrane of dystrophic muscle were decreased with age of the animal [230]. Likewise, some investigators have shown an increase [231] whereas others have observed a decrease in the Na\(^+\)-K\(^+\) ATPase activity in dystrophic muscle [232]. Such variable changes in the SL enzyme activities may be due to the type or age of dystrophic animals. In fact, a variety of changes in other SL components have been identified in dystrophic muscle [233, 234]. Taken together, all these observations support the view that increased Ca\(^{2+}\)-influx through the plasma membrane of dystrophic muscle may be a consequence of SL remodeling during the development of muscular dystrophy.

The impaired function of dystrophic muscle is generally considered to be due to Ca\(^{2+}\)-handling abnormalities in myocytes. Since the SR is intimately involved in maintaining the intracellular Ca\(^{2+}\)-homeostasis, different defects in this intracellular organelle have been identified in muscular dystrophy. Marked alterations in the structure and function of Ca\(^{2+}\)-release channel or ryanodine receptor in the SR have been demonstrated in dystrophic muscle [235–237]. A progressive increase in the expression of ryanodine receptor and ryanodine receptor binding in the SR has been shown to occur during the development of muscular dystrophy [238]. The leaky ryanodine receptors in dystrophic muscle have been indicated to limit the activation of SOCE channels and produce changes in Ca\(^{2+}\)-homeostasis [239]. It should also be noted that drastic reductions in both sarcalumenin and calsequestrin have been reported in dystrophic muscle to depress Ca\(^{2+}\)-binding in the lumen of SR and are considered to play a role in abnormal Ca\(^{2+}\)-handling in muscular dystrophy [240, 241]. Some investigators have shown marked depressions in the SR ATP-dependent Ca\(^{2+}\)-uptake and Ca\(^{2+}\)-pump ATPase activities in dystrophic muscle [242–245], whereas others have failed to observe such defects [246–248]. Such conflicting results may be due to the stage or type of muscular dystrophy. However, the depression in the Ca\(^{2+}\)-transport in the SR can be seen to occur because of the increased expression of sarcoplin, a known endogenous inhibitor of Ca\(^{2+}\)-pump ATPase, in dystrophic muscle [249–251]. Although calmodulin mRNA and content in dystrophic muscle are increased, the stimulation of the SR Ca\(^{2+}\)-pump ATPase by calmodulin is markedly depressed [252]. Thus, a reduction of Ca\(^{2+}\)-transport in the SR may also contribute to eliciting Ca\(^{2+}\)-handling abnormalities in dystrophic muscle. In this regard, it is noteworthy that an overexpression of the SR Ca\(^{2+}\)-pump ATPase has been
demonstrated to alter intracellular Ca\(^{2+}\) levels in dystrophic muscle and mitigate muscular dystrophy [181].

The development of Ca\(^{2+}\)-handling abnormalities in dystrophic muscle has been considered to affect other subcellular organelles such as mitochondria and myofibrils. In fact, mitochondrial dysfunction has been shown to occur before the onset of myofiber necrosis, muscle wasting and myofibrillar defects [253]. Impaired substrate utilization and ATP synthesis have been reported in dystrophic mitochondria [254, 255]. There occurs an uncoupling in the process of mitochondrial oxidative phosphorylation during the progression of muscular dystrophy [256, 257]. Although the development of mitochondrial Ca\(^{2+}\)-overload is considered to induce defects in energy production in dystrophic muscle [41], abnormalities in ATP synthesis by dystrophic mitochondria have also been shown to be caused by complex I insufficiency [258], disruption of mitochondrial protein Mss51 [259] and decreased CK content [260]. It is pointed out that the impaired performance of dystrophic muscle is not only a consequence of depressed energy stores but defects in the process of energy utilization have also been observed during the development of muscular dystrophy. In this regard, myofibrillar Ca\(^{2+}\)-stimulated ATPase and myosin ATPase activities have been shown to be decreased in dystrophic muscle [261, 262]. A shift in myosin heavy chain from alpha to beta isoform as well as changes in troponin-tropomyosin isoforms have been reported to cause alterations in dystrophic myofibrillar ATPase activities [263, 264]. Increased Ca\(^{2+}\)-activated protease activity in dystrophic muscle has also been shown to induce myofibrillar defects [100, 101, 265, 266].

It is becoming clear that Ca\(^{2+}\)-handling abnormalities in dystrophic muscle are associated with various defects in the subcellular organelles. Such alterations have been suggested to be caused by abnormalities of lipid metabolism in dystrophic muscle [78–88, 267, 268]. It may be mentioned that marked changes in cholesterol, triglycerides, unsaturated fatty acids and phospholipid content have been observed in dystrophic muscle [269–272]. Furthermore, increased oxidative stress in dystrophic muscle [172, 191, 273, 274] has been suggested to account for inducing remodeling and Ca\(^{2+}\)-handling abnormalities. It is pointed out that the expression of NAPDH oxidase, which generates ROS, is markedly increased in addition to mitochondrial oxycrissal production in dystrophic muscle [275, 276]. Furthermore, synergistic interactions of nitrosative/oxidative stresses due to increased neural nitric oxide synthase in dystrophic muscle [277, 278], have been indicated to be involved in Ca\(^{2+}\)-handling abnormalities during the development of muscular dystrophy.

7. Strategies for the treatment of muscular disorder

Corticosteroids therapy was reported for the first time to delay the progression of muscular disorder and was considered as the gold standard for its treatment [279]. Because almost all types of muscular dystrophies are caused by a single-gene mutation [280], gene therapy was also introduced as a potential intervention to replace, repair or bypass the mutated gene [281, 281–283]. In order to restore an appropriate level of dystrophin in skeletal muscle, different gene strategies have been based on implantation and delivery of naked plasmid DNA for the dystrophin gene [284–288], by adeno-associated virus (AAV) [289] as well as exon-skipping with antisense oligonucleotides [290–292]. Due to challenges like targeted delivery of therapeutic molecules, lysosomal setup, enzymatic degradation as well as low intracellular uptake, successful working with gene therapy has stimulated the search for different drug delivery systems such as polymersomes [293, 294], liposomes and lipid-nucleic acid complexes [295–297], PMMA nanoparticles [296, 298], and cell-penetrating peptides [290, 298, 299]. While a great progress has been made with gene therapy [12, 300], other interventions such as injections of myoblasts (derived from healthy donors) did not induce beneficial effects due to low survivability, migration and immune rejection of the transplanted cells; thus stem cells based therapies have been suggested for the treatment of diverse muscular disorders [301, 302]. Furthermore, various molecular pathways have been shown to be most befitting for the development of novel medicinal products to prevent muscle degeneration and fibrosis. The genetic modifiers including LTBP4, Jagged1 and osteopontin, which regulate the disease progression by interfering with pro-fibrotic and pro-regenerative pathways (TGF-β, myostatin and Notch signaling), have also offered a platform to identify novel pharmacological targets for the therapy of muscular weakness [303, 304]. Thus, several approaches (Fig. 3) are considered worthwhile for not only preventing the progression of this disorder but also the improvement of dystrophic muscle performance.

It is noteworthy that, recent data have shown better efficiency of gene therapy when high doses are administered [287]. Although high doses are fairly tolerated and achieve adequate transgene expression, these lack adequate balance of safety and efficacy for the success of gene therapy [305]. Clinical trials have shown a slight risk of liver toxicity represented by transient elevation in liver enzymes and bilirubin as side effects in humans subjected to such a gene therapy. Furthermore, the major obstacle for gene therapy is the pre-existing immune reaction to AAV, which is used as a vehicle; but the use of plasmapheresis was found to evade the immune reaction to AAV and this was considered to allow safe administration of gene therapy to patients with impaired muscular function [306]. Although, there is some optimism for utilizing plasmapheresis or T-cell suppression by agents such as rituximab and rapamycin to overcome the pre-existing immunity, the success of these approaches remains to be clearly demonstrated [307]. One of the shortcomings for the use of AAV is its limited packaging capacity for dystrophin molecule, which necessitated the development of a shorter protein, mini-dystrophin [308]. The construction of mini-dystrophin was based on the shortened dystrophin pro-
tein as expressed in dystrophic muscle and found to be highly functional [309]. Although mini-dystrophin gene therapy was shown to improve the systemic muscle function at early stages, it was only effective partially in advanced cases of muscular disease [308]. Such observations suggest that restoring muscle function to near-normal levels with gene therapy will probably necessitate additional research to improve and enhance the muscle strength in dystrophic muscle.

Since the intricacy of numerous mutations of dystrophin gene causes several challenges for the dystrophin gene therapy, a great deal of experimental work is needed for having an effective treatment of muscular disorder. Furthermore, it should be recognized that deficiency of laminin—alpha 2 protein has also been reported in dystrophic muscle and this was shown to be attenuated by omigapil, an antiplatelet agent [23]. Thus, it is likely that some combination gene therapy may prove more beneficial in delaying the course of this disease progression. It is also pointed out that pathological lesions in dystrophic muscle were found to be associated with marked increase in Ca$^{2+}$ content but these changes were not prevented with verapamil treatment, a well known antagonist of voltage sensitive Ca$^{2+}$-channels in the SL membrane [147]. On the other hand, reduction of Ca$^{2+}$-influx through SOCE channels was found to improve function in diseased muscle [185, 189]. Reintroduction of mini-dystrophin in dystrophic muscle was also reported to reduce Ca$^{2+}$ transients as a consequence of its effect on SOCE channels [192]. In addition, inhibition of phospholipase A$_2$ as well as lysophosphatidylcholine production was shown to depress Ca$^{2+}$-entry and prevent the degeneration of dystrophic muscle [190]. It should be mentioned that diapocynin, an inhibitor of NADPH oxidase, which reduces the production of ROS, was observed to depress the phospholipase A$_2$ activity as well as Ca$^{2+}$-influx through SOCE channels in dystrophic muscle. Accordingly, it is suggested that gene therapy in combination with some inhibitors of Ca$^{2+}$-entry and oxidative stress may be more effective for the treatment of muscular disorder.

8. Conclusions and future perspectives

From the foregoing discussion, it is evident that muscular dystrophy is a group of complex diseases, which results in skeletal muscle degeneration, loss of muscle fibers and impaired muscle function. Some forms of muscular dystrophy are considered to be a consequence of a genetic defect leading to deficiency of dystrophin for inducing abnormalities in the SL membrane. The progression of this disease is associated with leakage of intracellular enzymes and other constituents, maldistribution of electrolyte content, marked metabolic alterations and development of necrosis, apoptosis as well as fibrosis in dystrophic skeletal muscle. The depression in the high energy stores as a consequence of the mitochondrial Ca$^{2+}$-overload, and abnormalities in the SR due to defects in Ca$^{2+}$-release channel and Ca$^{2+}$-pump ATPase are considered to explain the impaired muscle performance. On the other hand, the activation of different proteolytic enzymes due to the occurrence of intracellular Ca$^{2+}$-overload is responsible for dystrophic muscle degeneration and wastage.
Some studies concerning defects in the SL membrane and other subcellular organelles as well as metabolic status of skeletal muscle have been conducted by employing a myopathic hamster model of muscular weakness. Other studies by using genetic mouse and chicken models of muscular dystrophy indicate that dystrophin deficiency induce the activation of SOCE channels, \( \text{Na}^+\text{-Ca}^{2+} \) exchanger (forward mode) and \( \text{Ca}^{2+}/\text{Mg}^{2+} \) ATPase (\( \text{Ca}^{2+} \)-gating system) in the SL membrane and promote the occurrence of intracellular \( \text{Ca}^{2+} \)-overload and subsequent abnormalities in dystrophic muscle. A schematic representation of some main events associated with the development as well consequence of intracellular \( \text{Ca}^{2+} \)-overload due to dystrophin-deficiency is shown in Fig. 4. Various, treatments including gene therapy with dystrophin and some pharmacological interventions such as antioxidants are being attempted for delaying the progression of this disease as well as improving the performance of dystrophic muscle. It is suggested that a combination therapy, by emplying dystrophin gene and some drugs, which reduce the development of intracellular \( \text{Ca}^{2+} \)-overload, may prove more beneficial for the treatment of impaired muscular performance.

**Author contributions**

NSD conceived, designed and edited the article; SKB searched the literature, analyzed the data and wrote the first draft; AKS and MN analyzed the data and wrote the manuscript.
Ethics approval and consent to participate
Not applicable.

Acknowledgment
The authors wish to thank Ms. Andrea Opsima for typing the manuscript.

Funding
There was no grant funding except the infrastructure support for this project was provided by the St. Boniface Hospital Research Foundation, Winnipeg, Canada.

Conflict of interest
The authors declare no conflict of interest.

References
[1] Emery AE. The muscular dystrophies. Lancet. 2002; 359: 687–695.
[2] Prosser EJ, Murphy EG, Thompson MW. Intelligence and the gene for Duchenne muscular dystrophy. Archives of Disease in Childhood. 1969; 44: 221–230.
[3] Conte G, Gioja L. Scrofola del sistema muscolare. Annali Clinici dell’Ospedale degli Incarabili di Napoli. 1836; 2: 266–279.
[4] Meryon E. On granular and fatty degeneration of the voluntary muscles. Medico-Chirurgical Transactions. 1852; 35: 73–84.
[5] Duchenne GB. Recherches sur la paralysie musculaire pseudo-hypertrophique ou paralysie mycosclerosique (pp. 5, 178, 305, 421, 552). Archives of General Internal Medicine. Paris: P. Asselin. 1868.
[6] Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, et al. Defective membrane repair in dystrophin-deficient muscular dystrophy. Nature. 2003; 423: 168–172.
[7] Bach JR, O’Brien J, Krottenberg R, Alba AS. Management of end stage respiratory failure in Duchenne muscular dystrophy. Muscle & Nerve. 1987; 10: 177–182.
[8] Heydemann A. Skeletal muscle metabolism in Duchenne and Becker muscular dystrophy-implications for therapies. Nutrients. 2018; 10: 1–25.
[9] Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe TB, et al. Diagnosis and management of Duchenne muscular dystrophy, Part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology. 2010; 9: 77–93.
[10] Gowers WR. Pseudo-hypertrophic muscular paralysis. A clinical lecture. London: Churchill. 1879.
[11] Erb W. Dystrophia muscularis progressiva. Deutsche Zeitschrift Für Nervenheilkunde. 1891; 1: 173–261.
[12] Gawlik KI. At the crossroads of clinical and preclinical research for muscular dystrophy—are we closer to effective treatment for patients? International Journal of Molecular Sciences. 2018; 19: 1409.
[13] Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2: 90–95.
[14] Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013; 381: 845–850.
[15] Crisafulli S, Sultana J, Fontana A, Salvo F, MESSINA S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet Journal of Rare Diseases. 2020; 15: 1–20.
[16] Gaeta M, Messina S, Mileto A, Vita GL, Ascenti G, Vinci S, et al. Muscle fat-fraction and mapping in Duchenne muscular dystrophy: Evaluation of disease distribution and correlation with clinical assessments: preliminary experience. Skeletal Radiology. 2012; 41: 955–961.
[17] Accorsi A, Kumar A, Rhee Y, Miller A, Girgenrath M. IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophy. Human Molecular Genetics. 2016; 25: 4624–4634.
[18] Palma E, Tiepolo T, Angelia A, Sabatelli P, Maraldi NM, Basso E, et al. Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice. Human Molecular Genetics. 2009; 18: 2024–2031.
[19] Cohn RD, Van Erp C, Habasiri JP, Soleimani AA, Klein EC, Lisi MT, et al. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nature Medicine. 2007; 13: 204–210.
[20] Jahnke VE, Van Der Meulen JH, Johnston HK, Ghimbovschi S, Partridge T, Hoffman EP, et al. Metabolic remodeling agents show beneficial effects in the dystrophic-deficient mdx mouse model. Skeletal Muscle. 2012; 2: 1–16.
[21] Cozzoli A, Nico B, Splendore JT, Capogrosso RF, Dinardo MM, Longo V, et al. Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice. Pharmacological Research. 2011; 64: 482–492.
[22] Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G, et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nature Medicine. 2008; 14: 442–447.
[23] Erb M, Meinen S, Barzaghi P, Sumanovski LT, Coudrier-Fruh I, Ruegg MA, et al. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. Journal of Pharmacology and Experimental Therapeutics. 2009; 331: 787–795.
[24] Girgenrath M, Beermann ML, Vishnudas VK, Homma S, Miller JB. Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Annals of Neurology. 2009; 65: 47–56.
[25] Rahimov F, Kunkel LM. The cell biology of disease: Cellular and molecular mechanisms underlying muscular dystrophy. Journal of Cell Biology. 2013; 201: 499–510.
[26] Chi MMY, Hintz CS, Mckee D, Felder S, Grant N, Kaisser KK, et al. Effect of Duchenne muscular dystrophy on enzymes of energy metabolism in individual muscle fibers. Metabolism. 1987; 36: 761–767.
[27] DePirro R, Lauro R, Testa I, Ferretti I, De Martino C, Dellantoni R. Decreased insulin receptors but normal glucose metabolism in Duchenne muscular dystrophy. Science. 1982; 216: 311–313.
[28] Perlolf JK, Henze E, Schelbert HR. Alterations in regional myocardial metabolism, perfusion, and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Circulation. 1984; 69: 33–42.
[29] van Bennekum C, Oerlemans FT, Kulakowski S, De Bruyn CH. Skeletal muscle metabolism in Duchenne-type muscular dystrophy. Journal of Biochemistry and Physiology. 1972; 50: 550–556.
[30] Follmann M, Fedele R, Toffler I. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nature Medicine. 2007; 13: 204–210.
[31] Dhallal NS, Fedeleova M, Toffler I. Biochemical alterations in the skeletal muscle of vitamin E deficient rats. Canadian Journal of Biochemistry. 1987; 66: 447–450.
[32] Radley-Grabb HG, Marini JC, Sosa HA, Castillo LI, Grounds MD, Fiorotto ML. Dystrophia muscularis progressiva. Deutsche Zeitschrift Für Nervenheilkunde. 1891; 1: 173–261.
[33] DePirro R, Lauro R, Testa I, Ferretti I, De Martino C, Dellantoni R. Decreased insulin receptors but normal glucose metabolism in Duchenne muscular dystrophy. Science. 1982; 216: 311–313.
E. Ozawa. Our trials and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era. Proceedings of the Japan Academy. 2010; 86: 798–821.

Murphy S, Ohlendieck K. Mass spectrometric identification of dystrophin, the protein product of the Duchenne muscular dystrophy gene, in distinct muscle surface membranes. International Journal of Molecular Medicine. 2017; 40: 1078–1088.

Turk R, Hisao JJ, Smits MM, Brandon H, Propisil TC, Jones KS, et al. Molecular signatures of membrane protein complexes underlying muscular dystrophy. Molecular & Cellular Journal of Proteomics. 2016; 15: 2169–2185.

Nigro V, Piluso G. Spectrum of muscular dystrophies associated with sarcolemmal-protein genetic defects. Biochimica et Biophysica Acta. 2015; 1852: 585–593.

Dhalla NS, Sulakhe PV. Calcium transport by the subcellular particles of the skeletal muscle of genetically dystrophic hamster. Biochimia Medica. 1973; 7: 159–168.

Wrogeaman, K, Pena SDJ. Mitochondrial calcium overload: a general mechanism for cell-necrosis in muscle diseases. Lancet. 1976; 1: 672–674.

Duncan CJ. Role of intracellular calcium in promoting muscle damage: a strategy for controlling the dystrophic condition. Experientia. 1978; 34: 1531–1535.

Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibres in 114 biopsies. Neurology. 1978; 28: 439–446.

Burr AR, Molkenit JD. Genetic evidence in the mouse solidifies the calcium hypothesis of myofiber death in muscular dystrophy. Cell Death & Differentiation. 2015; 22: 1402–1412.

Kurebayashi N, Ogawa Y. Depletion of Ca²⁺ in the sarcomplasmic reticulum stimulates Ca²⁺ entry into mouse skeletal muscle fibres. The Journal of Physiology. 2001; 533: 185–199.

Constantin B, Sebille S, Cognard C. New insights in the regulation of calcium transfers by muscle dystrophin-based cytoskeleton: Implications in DMD. Journal of Muscle Research and Cell Motility. 2006; 27: 375–386.

Hofp FW, Turner PR, Steinhardt RA. Calcium misregulation and the pathogenesis of muscular dystrophy. Calcium Signalling and Alzheimer’s Disease. 2007; 45: 429–464.

Putney Jr JW. Capacitative calcium entry revisited. Cell Calcium. 1990; 11: 611–624.

Sudevan S, Takiura M, Kubota Y, Higashitani N, Cooke M, Ellwood RA, et al. Mitochondrial dysfunction causes Ca²⁺ overload and ECM degradation–mediated muscle damage in C elegans. FASEB Journal. 2019; 33: 9540–9550.

Renjini R, Gayathri N, Nalini A, Srinivas Bhirath MM. Oxidative damage in muscular dystrophy correlates with the severity of the pathology: role of glutathione metabolism. Neurochemical Research. 2012; 37: 885–898.

L.Wells. The o-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy. Journal of Biological Chemistry. 2013; 288: 6930–6935.

Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L. Hypernitrrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nature Medicine. 2009; 15: 325–330.

Rowland LP, Osnos M, Hirschberg E. Serum enzymes in the myopathies. Transactions of the American Neurological Association. 1960; 85: 15–18.

Dreyfus JC, Schapira G. Biochemistry of hereditary myopathies. Thomas. 1962.

Pearson CM. Histopathological features of muscle in the preclinical stages of muscular dystrophy. Brain. 1962; 85: 109–120.

Dowling P, Murphy S, Zweeney M, Rauccamp M, Swardulla D, Ohlendieck K. Emerging proteomic biomarkers of X-linked muscular dystrophy. Expert Review of Molecular Diagnostics. 2019; 19: 739–755.

Hatouth Y, Marathi RL, Rayavarapu S, Zhang A, Brown KJ, Seol H. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Human Molecular Genetics. 2014; 23: 6458–6469.

Moat SJ, Korpimäki T, Furu P, Hakala H, Polari H, Meriö L, Mäkinen P. Weeks I. Characterization of a blood spot creatine kinase skeletal muscle isoform immunoassay for high-throughput newborn screening of Duchenne muscular dystrophy. Clinical Chemistry. 2017; 63: 908–914.

Thangaraj M, Zhang A, Gill K, Ressom HW, Li Z, Varghese RS, et al. Discovery of potential urinary-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne. PLoS ONE. 2019; 14: 1–17.

Aartsma-Rus A, Ferlini A, McNally EM, Spitali P, Sweeney HL, et al. Biomarkers of Duchenne muscular dystrophy. Expert Review of Molecular Diagnostics. 2019; 20: 78–86.

Aartsma-Rus A, Spitali P. Circulating biomarkers for Duchenne muscular dystrophy. Journal of Neuromuscular Diseases. 2015; 2: 495–558.

Lourbakos A, Yau N, de Bruijn P, Hiller M, Kozacynska K, Jean-Baptiste R, et al. Evaluation of serum MMP-9 as predictive biomarker for antiangiogenesis therapy in Duchenne. Scientific Reports. 2017; 7: 17888.

Szigiarto CA, Spitali P. Biomarkers of Duchenne muscular dystrophy: current findings. Degenerative Neurological and Neuromuscular Disease. 2018; 8: 1–13.

Al-Khalil Szigiarto C. Duchenne muscular dystrophy: recent advances in protein biomarkers and the clinical application. Expert Review of Journal of Proteomics. 2020; 17: 365–375.

Mokri B, Engel WA. Duchenne dystrophy: electronmicroscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology. 1975; 23: 1111–1120.

Obere MA, Engel WK. Ultrastructural localization of calcium in normal and abnormal skeletal muscle. Laboratory Investigation. 1977; 36: 566–577.

Munsat TL, Baloh R, Pearson CM, Fowler Jr, Jr. Serum enzyme alterations in neuromuscular disorders. The Journal of the American Medical Association. 1973; 226: 1536–1542.

Roy S, Dubowitz V. Carrier detection in Duchenne muscular dystrophy. A comparative study of electron microscopy, light microscopy and serum enzymes. Journal of the Neurological Sciences. 1970; 11: 65–79.

Ohlendieck K. Emerging proteomic biomarkers of X-linked muscular dystrophy gene, in distinct muscle surface membranes. International Journal of Molecular Medicine. 2010; 86: 798–821.

Rowland LP, Osnos M, Hirschberg E. Serum enzymes in the myopathies. Transactions of the American Neurological Association. 1960; 85: 15–18.

Dreyfus JC, Schapira G. Biochemistry of hereditary myopathies. Thomas. 1962.

Pearson CM. Histopathological features of muscle in the preclinical stages of muscular dystrophy. Brain. 1962; 85: 109–120.

Dowling P, Murphy S, Zweeney M, Rauccamp M, Swardulla D, Ohlendieck K. Emerging proteomic biomarkers of X-linked muscular dystrophy. Expert Review of Molecular Diagnostics. 2019; 19: 739–755.
Klymiuk N, Blutke A, Krause S, Burkhardt K, Wenusch A, et al. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Human Molecular Genetics. 2013; 22: 4368–4382.

Selby JT, Ross JW, Nonneman D, Hollinger K. Porcine models of muscular dystrophy. ILAR Journal. 2015; 56: 116–126.

Larcher T, Lafoux A, Tesson L, Remy S, Thenepen V, Francois V, et al. Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS ONE. 2014; 9: 1–13.

Nakamura K, Fujii W, Tsobui M, Tanihata J, Teramoto N, Takeuchi S, et al. Generation of muscular dystrophy model rats with a CRISPR/Cas system. Scientific Reports. 2014; 4: 5635.

Miyazato LG, Moraes JR, Beretta DC, Kornegay JN. Muscular dystrophy in dogs: does the crossing of breeds influence disease phenotype? Veterinary Pathology. 2011; 48: 655–662.

Korngay JN. The golden retriever model of Duchenne muscular dystrophy. Skeletale Muscle. 2017; 7: 1–21.

Brinkmeyer-Langford C, Korngay JN. Comparative genomics of X-linked muscular dystrophies: the golden retriever model. Current Genomics. 2015; 14: 330–342.

Carpenter JL, Hoffman EP, Romanul FC, Kunel LM, Rosales RK, Ma NS, et al. Feline muscular dystrophy with dystrophin deficiency. The American Journal of Pathology. 1989; 135: 909–919.

Gaschen FP, Hoffman EP, Gorospe JR, Uh EW, Senior DF, Cardinet GH, et al. Dystrophin deficiency causes lethal muscle hypertrophy in cats. Journal of the Neurological Sciences. 1992; 110: 149–159.

Ge Y, Molloy MP, Chamberlain JS, Andrews PC. Proteomic analysis of mdx skeletal muscle: great reduction of adenyate kinase 1 expression and enzymatic activity. Journal of Proteomics. 2003; 3: 1895–1903.

Watt MJ, Hoy AJ. Lipid metabolism in skeletal muscle: generation of adaptive and maladaptive intracellular signals for cellular function. The American Journal of Physiology-Endocrinology and Metabolism. 2012; 302: E1315–E1328.

Chinet A, Even P, Decrouy A. Dystrophin-dependent efficiency of metabolic pathways in mouse skeletal muscles. Cellular and Molecular Life Sciences. 1994; 50: 602–605.

Onopuch K, Brutkowski W, Wierzbicka K, et al. Mutation in dystrophin encoding gene affects energy metabolism in mouse myoblasts. Biochemical and Biophysical Research Communications. 2009; 386: 463–466.

Raith M, Valencia RG, Fischer I, Orthofer M, Penninger JM, Spuler S, et al. Linking cytoarchitecture to metabolism: sarcoglycan-associated plectin affects glucose uptake by destabilizing microtubule networks in mdx myoblasts. Skeletale Muscle. 2013; 3: 1–14.

Glebsky MJ, Rosenmann E, Nylen EG, Wrogemann K, Serum CK. Calcium, magnesium, and oxidative phosphorylation in mdx mouse muscular dystrophy. Muscle & Nerve. 1988; 11: 852–856.

Kuznetsov AV, Winkler K, Wiedemann F, von Bossanyi P, Dietrich CM, Kornegay JN. Comparative genomics of X-linked muscular dystrophies: the golden retriever model. Current Genomics. 2015; 14: 330–342.

Carpenter JL, Hoffman EP, Romanul FC, Kunel LM, Rosales RK, Ma NS, et al. Feline muscular dystrophy with dystrophin deficiency. The American Journal of Pathology. 1989; 135: 909–919.

Gaschen FP, Hoffman EP, Gorospe JR, Uh EW, Senior DF, Cardinet GH, et al. Dystrophin deficiency causes lethal muscle hypertrophy in cats. Journal of the Neurological Sciences. 1992; 110: 149–159.

Ge Y, Molloy MP, Chamberlain JS, Andrews PC. Proteomic analysis of mdx skeletal muscle: great reduction of adenyate kinase 1 expression and enzymatic activity. Journal of Proteomics. 2003; 3: 1895–1903.

Watt MJ, Hoy AJ. Lipid metabolism in skeletal muscle: generation of adaptive and maladaptive intracellular signals for cellular function. The American Journal of Physiology-Endocrinology and Metabolism. 2012; 302: E1315–E1328.

Chinet A, Even P, Decrouy A. Dystrophin-dependent efficiency of metabolic pathways in mouse skeletal muscles. Cellular and Molecular Life Sciences. 1994; 50: 602–605.

Onopuch K, Brutkowski W, Wierzbicka K, et al. Mutation in dystrophin encoding gene affects energy metabolism in mouse myoblasts. Biochemical and Biophysical Research Communications. 2009; 386: 463–466.

Raith M, Valencia RG, Fischer I, Orthofer M, Penninger JM, Spuler S, et al. Linking cytoarchitecture to metabolism: sarcoglycan-associated plectin affects glucose uptake by destabilizing microtubule networks in mdx myoblasts. Skeletale Muscle. 2013; 3: 1–14.
Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90: 3710–3714.

Putney JW. Pharmacology of store-operated calcium channels. Frontiers in Bioscience. 2011; 3: 980–984.

Edwards RN, Friedrich O, Cully TR, Von Wegner F, Murphy RM, Launikonis BS, et al. Upregulation of store-operated Ca\(^{2+}\) entry in dystrophic mdx mouse muscle. American Journal of Physiology-Cell Physiology. 2010; 299: C42–C50.

Stiber JA, Rosenberg PB. The role of store-operated calcium influx in skeletal muscle signaling. Cell Calcium. 2011; 49: 341–349.

Goonasekera SA, Lam CK, Millay DP, Sargenta MG, Hajar RJ, Kranias EG, et al. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. Journal of Clinical Investigation. 2011; 121: 1044–1052.

Trebak M, Zhang W, Ruhle B, Henkel MM, Gonzalez-Cobos JC, Motiana RK, et al. What role for store operated Ca\(^{2+}\) entry in muscle? Microcirculation. 2013; 20: 330–336.

Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signaling. Nature Reviews Molecular Cell Biology. 2000; 1: 11–21.

Franco Jr A, Lansman JB. Calcium entry through stretch-inactivated ion channels in mdx myotubes. Nature. 1990; 344: 670–673.

Millay DP, Goonasekera SA, Sargenta MA, Maillet M, Aronow BJ, Morkent DJ, et al. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106: 19023–19028.

Durbeej M, Campbell KP. Muscular dysfunctions involving the dystrophin-glycoprotein complex: an overview of current mouse models. Current Opinion in Genetics and Development. 2002; 12: 349–361.

Boitnott FX, Petermann O, Hirm C, Mittaud P, Dorchies OM, et al. Ultrastructure and calcium transport in dystrophic chicken muscle microsomes. Laboratory Investigation. 1970; 23: 581–589.

Peter JB, Worsfold M. Muscular dystrophy and other myopathies: sarcotubular vesicles in early disease. Biochemistry Medica. 1969; 2: 364–371.

Martonosi A. Sarcolemmal reticulum. VI. Microsomal Ca\(^{2+}\) transport in genetic muscular dystrophy of mice. Experimental Bi- ology and Medicine. 1968; 127: 824–828.

Hsu QS, Kaldor G. Studies on the sarcolemmal reticulum of normal and dystrophic animals. Experimental Biology and Medicine. 1969; 131: 1398–1402.

Baskin RJ. Ultrastructure and calcium transport in dystrophic muscle oxidative stress and improves grip strength in dysferlin- Mdx mice is reduced by ion channel blockers. The Journal of Phys- iology-Cell Physiology. 2010; 299: C42–C50.

Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca\(^{2+}\), reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiological Reviews. 2016; 96: 253–305.

Garcia-Campos p, Baez-Matus X, Jara-Gutierrez C, Paz-Araos M, Astorga C, Cea LA, et al. N-Acetylcycteine reduces skeletal muscle oxidative stress and improves grip strength in dystferlin-deficient Bla/J mice. International Journal of Molecular Sciences. 2020; 21: 4293.

Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell. 1991; 66: 1121–1131.

Froehner SC. Just say NO to muscle degeneration? Trends in Molecular Medicine. 2002; 8: 51–53.

Petrof BJ, Shragar JB, Sedman HH, Kelly AM, Sweeney HL. Dys-
skeletal muscle in mice. Molecular and Cellular Biology. 2012; 32: 3009–3017. [196] Wei-Lapierre L, Carrell EM, Boncompagni S, Protasi F, Dirksen RT. Orai1-dependent calcium entry promotes skeletal muscle growth and limits fatigue. Nature Communications. 2013; 4: 1–24. [197] Carrell EM, Coppola AR, McBride HJ, Dirksen RT. Orai1 enhances muscle endurance by promoting fatigue-resistant type I fiber content but not through acute store-operated Ca²⁺ entry. FASEB Journal. 2016; 30: 4109–4119. [198] Lyfenko AD, Dirksen RT. Differential dependence of store-operated and excitation-coupled Ca²⁺ entry in skeletal muscle on STIM1 and Orai1. The Journal of Physiology. 2008; 586: 4815–4824. [199] Sibier J, Hawkins A, Zhang Z-S, Wang S, Burch J, Graham V, et al. STIM1 signalling controls store-operated calcium entry required for development and contractile function in skeletal muscle. Nature Cell Biology. 2008; 10: 688–697. [200] Liou J, Kim ML, Do Heo W, Jones JT, Myers JW, Ferrell Jr JE, et al. STIM1 is a Ca²⁺ sensor essential for Ca²⁺–store-depletion-triggered Ca²⁺ influx. Current Biology. 2005; 15: 1235–1241. [201] Zhang SL, Yu Y, Roos J, Kozak JA, Deerinck TJ, Ellisman MH, et al. STIM1 is a Ca²⁺ sensor that activates CRAC channels and migrates from the Ca²⁺ store to the plasma membrane. Nature. 2005; 437: 902–905. [202] Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. Orai1 is an essential pore subunit of the CRAC channel. Nature. 2006; 443: 226–229. [203] Yeromin AV, Zhang SL, Jiang W, Yu Y, Safrina O, Cahalan MD. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature. 2006; 443: 1220–1223. [204] Vig M, Peinelt C, Beck A, Koomoa DL, Rabab D, Koblan-Huberson M, et al. CRACM1 is a plasma membrane protein essential for store-operated Ca²⁺ entry. Science. 2006; 312: 1220–1223. [205] Soboloff J, Rothberg BS, Madesh M, Gill DL. STIM proteins: dynamic calcium signal transducers. Nature Reviews Molecular Cell Biology. 2012; 13: 549–565. [206] Michelucci A, Garcia-Castañeda M, Boncompagni S, Dirksen RT. Role of STIM1/ORAI1-mediated store-operated Ca²⁺ entry in skeletal muscle physiology and disease. Cell Calcium. 2018; 76: 101–115. [207] Kiviluoto S, Decuyper JP, De Smedt H, Missiaen L, Parys JB, Bultynck G. STIM1 as a key regulator for Ca²⁺ homeostasis in skeletal muscle development and function. Skeletal Muscle. 2011; 1: 1–16. [208] Darbellay B, Arnaudeau S, König S, Joussel H, Bader C, Demauvrex N, et al. STIM1–and Orai1-dependent store-operated calcium entry regulates human myoblast differentiation. Journal of Biological Chemistry. 2009; 284: 5370–5380. [209] Lee KJ, Woo JS, Hwang J-H, Hyun C, Cho C-H, Kim DH, et al. STIM1 negatively regulates Ca²⁺ release from the sarcoplasmic reticulum in skeletal myotubes. Biochemical Journal. 2013; 453: 187–200. [210] Boncompagni S, Michelucci A, Pietrangeli L, Dirksen RT, Protasi F. Exercise-dependent formation of new junctions that promote STIM1–Orai1 assembly in skeletal muscle. Scientific Reports. 2017; 7: 1–12. [211] Yarotsky V, Dirksen RT. Temperature and RyR1 regulate the activation rate of store-operated Ca²⁺ entry current in myotubes. Biophysical Journal. 2012; 103: 202–211. [212] Szttoray M, Geyer N, Vincez J, Al-Gaedi D, Oláh T, Szentesi P, et al. SOCE is important for maintaining sarcoplasmic calcium content and release in skeletal muscle fibers. Biophysical Journal. 2017; 113: 2496–2507. [213] Zhao X, Yoshida M, Brotto L, Takeshima H, Weisleder N, Hiyata Y, et al. Enhanced resistance to fatigue and altered calcium handling properties of sarcalumenin knockout mice. Physiological Genomics. 2005; 23: 72–78. [214] Goonasekera SA, Davis J, Kwong JQ, Accornero F, Wei-La Pierre L, Sargent MA, et al. Enhanced Ca²⁺ influx from STIM1–Orai1 induces muscle pathology in mouse models of muscular dystrophy. Human Molecular Genetics. 2014; 23: 3706–3715. [215] Cully TR, Edwards JN, Friedrich O, Stephenson DG, Murphy RM, Launikonis BS. Changes in plasma membrane Ca²⁺–ATPase and stromal interacting molecule 1 expression levels for Ca²⁺ signaling in dystrophic mdx mouse muscle. American Physiological Society Journal Cell Physiology. 2012; 303: C567–C576. [216] Zhao X, Moloughney JG, Zhang S, Komazaki S, Weisleder N. Orai1 mediates exacerbated Ca²⁺ entry in dystrophic skeletal muscle. PLoS ONE. 2012; 7: e94962. [217] Avila-Medina J, Mayoral-Gonzalez I, Dominguez-Rodriguez A, Gallardo-Castillo I, Ribas J, Ordonez A, et al. The complex role of stored operated calcium entry pathways and related proteins in the function of cardiac, skeletal and vascular smooth muscle cells. Frontiers in Physiology. 2018; 9: 1–14. [218] Sabourin J, Harisse R, Harnois T, Magaud C, Bourmeyster N, Deliot N, et al. Dyrophosphoinositol-5-phosphate regulated PLC/PKC-dependent store-operated calcium entry in myotubes. Cell Calcium. 2012; 52: 445–456. [219] Balghi H, Sibille S, Mondin L, Cantareau A, Constantin B, Raymond G, et al. Mini-dystrophin expression down-regulates IP₃-mediated calcium release events in resting dystrophin-deficient muscle cells. The Journal of General Physiology. 2006; 128: 219–230. [220] Gazzero E, Baratto S, Assereto S, Baldassarri S, Panucci C, Raffaghello I, et al. The danger signal extracellular ATP is involved in the immunomodulated damage of α-sarcoglycan-deficient muscular dystrophy. The American Journal of Pathology. 2019; 189: 354–369. [221] Fraysse B, Lianontio A, Cetrone M, Burdi R, Frigeri A, et al. The alteration of calcium homeostasis in adult dystrophic mdx muscle fibers is worsened by a chronic exercise in vivo. Neurobiology of Disease. 2004; 17: 144–154. [222] Allard B, Couchoux H, Pouvreau S, Jacquesmon V. Sarcoplasmic reticulum Ca²⁺ release and depletion fail to affect sarcoclemmal ion channel activity in mouse skeletal muscle. The Journal of Physiology. 2006; 575: 69–81. [223] Turner PR, Fong PY, Denetclaw WF, Steinhardt RA. Increased calcium influx in dystrophic muscle. Journal of Cell Biology. 1991; 151: 1701–1712. [224] Noireaud J, Leoty C, Na₄/–Ca²⁺ exchange in limb muscles of dystrophic (c57/B6/j)2/d2y/j2) mice. Quarterly Journal of Experimental Physiology. 1989; 74: 75–77. [225] Dunn JF, Bannister N, Kemp GJ, Publicover SJ. Sodium is elevated in mdx muscles: ionic interactions in dystrophic cells. Journal of the Neurological Sciences. 1993; 114: 76–80. [226] Lin CH, Hudson AJ, Strickland KP. Adenyl cyclase and cyclic nucleotide phosphodiesterase activities in murine muscular dystrophy. Enzyme. 1976; 21: 85–95. [227] Yeung D, Zablcki K, Lien CF, Jiang T, Arkle S, Bruttowski W. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscles. FASEB Journal. 2006; 20: 610–620. [228] Iwata Y, Katanosaka Y, Hisamitsu T, Wakabayashi S. Enhanced Na⁺/H⁺ exchange activity contributes to the pathogenesis of muscular dystrophy via involvement of P2 receptors. The American Journal of Pathology. 2007; 171: 1576–1587. [229] Young NJC, Bruttowski W, Lien CF, Arkle S, Lochmuller H, Zablcki K, et al. P2X₇ purinoceptor alterations in dystrophic mdx mouse muscles: raelationship to pathology and potential target for treatment. Journal of Cellular and Molecular Medicine. 2012; 16: 1026–1037. [230] Malouf NN, Samsa D, Allen R, Meissner G. Biochemical and cytotoxic comparison of surface membranes from normal and dystrophic chickens. The American Journal of Pathology. 1981; 105: 223–231.
Dunn JF, Burton KA, Dauncey MJ. Ouabain sensitive Na\textsuperscript{+}/K\textsuperscript{+} ATPase content is elevated in mdx mice: implications for the regulation of ions in dystrophic muscle. Journal of the Neurological Sciences. 1995; 133: 11–15.

Miles MT, Cottey E, Cottey A, Stefanksi C, Carlson CG. Reduced resting potentials in dystrophic (mdx) muscle fibers are secondary to NF-κB-dependent negative modulation of ouabain sensitive Na\textsuperscript{+}/K\textsuperscript{+} pump activity. Journal of the Neurological Sciences. 2011; 303: 53–60.

Takamure M, Murata KY, Tamada Y, Azuma M, Ueno S. Calpain-dependent alpha-fodrin cleavage at the sarcosome in muscle diseases. Muscle & Nerve. 2005; 32: 303–309.

Murphy S, Zweyer M, Henry M, Meleady P, Mundegar RR, Swandulla D. Proteomic analysis of the sarcosome-enriched fraction from dystrophic mdx-4cv skeletal muscle. Journal of Proteomics. 2019; 191: 212–227.

Santulli G, Lewis D, des Georges A, Marks AR. Ryanodine receptor structure and function in health and disease. Subcellular Biochemistry. 2018; 87: 329–352.

Lawal TA, Todd JJ, Witherspoon JW, Bonnemann CG, Dowling JJ, Hamilton SL. Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature. Skeletal Muscle. 2020; 10: 32.

Robin G, Berthier C, Allard B. Sarcoplasmic reticulum Ca\textsuperscript{2+} permeation explored from the lumen in mdx muscle fibers under voltage control. The Journal of General Physiology. 2012; 139: 209–218.

Presah IN, Schiedt MJ. Early over-expression of low-affinity [3H]ryanodine receptor sites in heavy sarcoplasmic reticulum fraction from dystrophic chicken pectoralis major. Biochimica et Biophysica Acta. 1990; 1023: 98–106.

Cully TR, Launikis BS. Leaky ryanodine receptors delay the activation of store overload-induced Ca\textsuperscript{2+} release, a mechanism underlying malignant hyperthermia-like events in dystrophic muscle. The American Journal of Physiology: Cell Physiology. 2016; 310: C673–C680.

Dowling P, Doran P, Ohlendieck K. Drastic reduction of sarcalumenin in D. p547 (dystrophin of 427 kDa)-deficient fibres indicates that abnormal calcium handling plays a key role in muscular dystrophy. Biochemical Journal. 2004; 379: 479–488.

Butcher LA, Tomkins JK. Protein profiles of sarcoplasmic reticulum from normal and dystrophic mouse muscle. Journal of the Neurological Sciences. 1986; 72: 159–169.

Etienne EM, Singer RH, Ca\textsuperscript{2+} binding, ATP-dependent Ca\textsuperscript{2+} transport, and total tissue Ca\textsuperscript{2+} in embryonic and adult avian dystrophic pectoralis. The Journal of Membrane Biology. 1978; 44: 195–210.

Hanna S, Kawamoto R, McNamme M, Baskin RJ. Enzymatic activity of dystrophic chicken sarcoplasmic reticulum. Biochimica et Biophysica Acta. 1981; 643: 41–54.

Kargacin ME, Kargacin GJ. The sarcoplasmic reticulum calcium pump is functionally altered in dystrophic muscle. Biochimica et Biophysica Acta. 1996; 1290: 4–8.

Kawamoto RM, Baskin RJ. Calcium transport, ATPase activity and lipid composition in sarcoplasmic reticulum isolated from isoegenic lines of normal dystrophic chickens. Biochimica et Biophysica Acta. 1983; 732: 620–626.

Khammari A, Pereon Y, Baudet S, Noireaud J. In situ study if the sarcoplasmic reticulum function in control and mdx mouse diaphragm muscle. Canadian Journal of Physiology and Pharmacology. 1998; 76: 1161–1165.

Guglielmi V, Oosterhof A, Voermans NC, Cardani R, Molenaar JP, van Kuppevelt TH. Characterization of sarcoplasmic reticulum Ca\textsuperscript{2+} ATPase pumps in muscle of patients with myotonic dystrophy and with hypothyroid myopathy. Neuromuscular Disorders. 2016; 26: 378–385.

Scates DJ, Sabbadini RA. Microsomal T system: a stereological analysis of purified microsomes derived from normal and dystrophic skeletal muscle. Journal of Cell Biology. 1979; 83: 33–46.

Schneider JB, Shamnugam M, Gonzalez JF, Lopez H, Gordan R, Fraidenraich D. Increased sarcolipin expression and decreased sarco(endo)plasmic reticulum Ca\textsuperscript{2+} uptake in skeletal muscle of mouse models of Duchenne muscular dystrophy. Journal of Muscle Research and Cell Motility. 2013; 34: 349–356.

Niranjan N, Mareedu S, Tian Y, Kodippili K, Fefelova N, Voit SV. Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature. Skeletal Muscle. 2020; 11: 90.

Thacore HR, Kibler PK, Hudecki MS, Galindo Jr J, Davis FB. Davis PJ. Early abnormal development of calmodulin gene expression and calmodulin-resistant Ca\textsuperscript{2+}-ATPase activity in avian dystrophic muscle. Biochemical and Biophysical Research Communications. 1988; 151: 1434–1440.

Moore TM, Lin AJ, Strumwasser AR, Cory K, Whitney K, Ho T. Mitochondrial dysfunction is an early consequence of partial or complete dystrophin loss in mdx mice. Frontiers in Physiology. 2020; 11: 90.

Bell EL, Shine RW, Dwyer P, Olson L, Truong J, Fredenburg R. PPARδ modulation rescues mitochondrial fatty acid oxidation defects in the mdx model of muscular dystrophy. Mitochondrion. 2019; 46: 51–58.

Martens ME, Jankulovska L, Nymark MA, Lee CP. Impaired substrate utilization in mitochondria from strain 129 dystrophic mice. Biochimica et Biophysica Acta. 1980; 589: 190–200.

Liang RC. Studies on mitochondria from dystrophic skeletal muscle of mice. Biochemical Medicine and Metabolic Biology. 1986; 36: 172–178.

Percival JM, Siegel MP, Knowels G, Marcinek DJ. Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDES inhibition. Human Molecular Genetics. 2013; 22: 153–167.

Rybalka E, Timpani CA, Cooke MB, Williams AD, Hayes A. Defects in mitochondrial ATP synthase in dystrophin-deficient mdx skeletal muscles may be caused by complex I insufficiency. PLoS ONE. 2014; 9: e115763.

Gonzalez YLR, Moyer AL, LeTexier NJ, Bratti AD, Feng S, Pena V. MSSI deletion increases endurance and alleviates histopathology in the mdx mouse model of Duchenne muscular dystrophy. FASEB Journal. 2021; 35: e21276.

Bennett VD, Hall N, DellaMorte K. Decreased mitochondrial creatine kinase activity in dystrophic chicken breast muscle alters creatine-linked respiratory coupling. Archives of Biochemistry and Biophysics. 1985; 24: 380–391.

Fink RH, Stephenson DG, Williams DA. Physiological properties of skinned fibres from normal and dystrophic (Duchenne) human muscle activated by Ca\textsuperscript{2+} and Sr\textsuperscript{2+}. The Journal of Physiology. 1990; 420: 337–353.

Reddy YS, Reddy NB, Mobley BA, Beese RC. Myofibrillar and membrane-bound enzymes in skeletal muscle from myodystrophic mice. The International Journal of Biochemistry & Cell Biology. 1992; 24: 579–584.

Murphy S, Zweyer M, Mundegar RR, Swandulla D, Ohlendieck K. Comparative gel-based proteomic analysis of chemically crosslinked complexes in dystrophic skeletal muscle. Electrophoresis. 2018; 39: 1735–1744.

Malhotra A. Role of regulatory proteins (troponin-tropomyosin) in pathologic states. Molecular and Cellular Biochemistry. 1994; 135: 43–50.
Hillgartner FB, Williams AS, Flanders JA, Morin D, Hansen RJ. Myofibrillar protein degradation in the chicken. 3-Methylhistidine release in vivo and in vitro in normal and genetically muscular-dystrophic chickens. Biochemical Journal. 1981; 196: 591–601.

Saini-Chohan HK, Mitchell RW, Vaz FM, Zelinski T, Hatch GM. Delianating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders. Journal of Lipid Research. 2012; 53: 4–27.

Srivastava NK, Yadav R, Mukherjee S, Pal L, Sinha N. Abnormal lipid metabolism in skeletal muscle tissue of patients with muscular dystrophy: in vitro, high-resolution NMR spectroscopy based observation in early phase of the disease. Magnetic Resonance Imaging. 2017; 38: 163–173.

Touboul D, Piednoel H, Voisin V, De La Porte S, Brunelle A, Halgand F. Changes of phospholipid composition within the dystrophic muscle by matrix-assisted laser desorption/ionization mass spectrometry and mass spectrometry imaging. European Journal of Mass Spectrometry. 2004; 10: 657–664.

Agarwal AK, Tunison K, Mitsche MA, McDonald JG, Garg A. Insights into lipid accumulation in skeletal muscle in dystrofin-deficient mice. Journal of Lipid Research. 2019; 60: 2057–2073.

Tuazon MA, Henderson GC. Fatty acid profile of skeletal muscle phospholipid is altered in mdx mice and is predictive of disease markers. Metabolism. 2012. 61: 801–811.

Anderson JE. Myotube phospholipid synthesis and sarcocellular ATPase activity in dystrophic (mdx) mouse muscle. Biochemistry and Cell Biology. 1991; 69: 835–841.

Spasov A, Grodes T, Gedrange T, Pavlovic D, Lupp A, Kunert-Keil C. Increased oxidative stress in dystrophin deficient (mdx) mice masticatory muscles. Experimental and Toxicologic Pathology. 2011; 63: 549–552.

Moulin M, Ferreiro A. Muscle redox disturbances and oxidative stress as pathomechanisms and therapeutic targets in early-onset myopathies. Seminars in Cell and Developmental Biology. 2017; 64: 213–223.

Turki A, Hayot M, Carnac G, Pillard F, Passier E, Bommart S. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction. Free Radical Biology and Medicine. 2012; 53: 1068–1079.

Bakke JE, Zhang L, Percival JM. Neuronal nitric oxide synthase (nNOS) splice variant function: insights into nitric oxide signaling from skeletal muscle. Nitric Oxide. 2019; 82: 35–47.

Dudley RWR, Danialou G, Govindaraju K, Lands L, Eidelman DE, Petrof BJ. Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses. The American Journal of Pathology. 2012; 181: 18168–18184.

Cox GA, Cole NM, Matsumura K, Phelps SF, Haushcka SD, Campbell KP, et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature. 1993; 364: 725–729.

Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Triﬁllis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007; 447: 87–91.

Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247: 1465–1468.

Romero NB, Benveniste O, Payan C, Braun S, Soubian P, Her son S, et al. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol. Neuromuscular Disorders. 2002; 12: 45–48.

Duan D. Myody, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy. Current Opinion in Molecular Therapeutics. 2008; 10: 86–94.

Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. The New England Journal of Medicine. 2017; 377: 1713–1722.

Yue Y, Pan X, Hakim CH, Kodippil K, Zhang K, Shin JH, et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Human Molecular Genetics. 2015; 24: 5880–5890.

Heath CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera AMC, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016; 351: 403–407.

Yin H, Betts C, Saleh AF, Ivanova GD, Lee H, Seow Y, et al. Optimization of nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Molecular Therapy. 2010; 18: 819–827.

Goyenvalle A, Griffith G, Babbs A, El-Andaloussi S, Ezzat K, Avril A, et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nature Medicine. 2015; 21: 270–275.

Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, et al. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Therapeutics. 2012; 22: 306–315.

Shen J, Wu X, Lee Y, Wolfgram J, Yang Z, Mao Z-W, et al. Porous silicon microparticles for delivery of siRNA therapeutics. Journal of Visualized Experiments. 2015; 95: 1–9.

Kim Y, Tewari M, Pajerowski JD, Cai S, Sen S, Williams JH, et al. Polymersome delivery of siRNA and antisense oligonucleotides. Journal of Controlled Release. 2009; 134: 132–140.

Afzal E, Zakeri S, Keyhaniwar P, Bagheri M, Mahjoubi P, Asa dian M, et al. Nanoparticle-based delivery of antisense oligonucleotides allowing restoration of dystrophin expression in the mdx mouse. Molecular Therapy. 2009; 17: 820–827.

Prakash TP, Lima WF, Murray HM, Elbashir S, Cantley W, Fos l et al. Neuronal nitric oxide synthase in stressed mdx dystrophic skeletal muscle fibers. Pflügers Archiv. 2009; 458: 915–928.

Drachman DB, Toya KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974; 2: 1409–1412.

Chamberlain JS. Gene therapy of muscular dystrophy. Human Molecular Genetics. 2002; 11: 2355–2362.

Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015; 20: 18168–18184.

Cox GA, Cole NM, Matsumura K, Phelps SF, Haushcka SD, Campbell KP, et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature. 1993; 364: 725–729.
[301] Seto JT, Bengtsson NE, Chamberlain JS. Therapy of genetic disorders—novel therapies for Duchenne muscular dystrophy. Current Pediatrics Reports. 2014; 2: 102–112.

[302] Bonfanti C, Rossi G, Tedesco FS, Giannotta M, Benedetti S, Tonlorenzi R, et al. PW1/Peg3 expression regulates key properties that determine mesangioblast stem cell competence. Nature Communications. 2015; 6: 1–13.

[303] Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM, Mendell JR, et al. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Annals of Neurology. 2013; 73: 481–488.

[304] Vieira NM, Elvers I, Alexander MS, Moreira YB, Eran A, Gomes JP, et al. Jagged 1 rescues the Duchenne muscular dystrophy phenotype. Cell. 2015; 163: 1204–1213.

[305] Asher DR, Thapa K, Dharia SD, Khan N, Potter RA, Rodino-Klapac LR, et al. Clinical development on the frontier: Gene therapy for Duchenne muscular dystrophy. Expert Opinion on Biological Therapy. 2020; 20: 263–274.

[306] Chicoine LG, Montgomery CL, Bremer WG, Shontz KM, Griffin DA, Heller KN, et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Molecular Therapy. 2014; 22: 338–347.

[307] de Feraudy Y, Yaou RB, Wabbi K, Leturcq F, Amthor H. Very low residual dystrophin levels mitigate dystrophinopathy towards Becker muscular dystrophy. Neuromuscular Disorders. 2019; 29: S89.

[308] Lotfinia M, Abdollahpour-Alitappeh M, Hatami B, Zali MR, Karimipoor M. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies. Clinical and Experimental Medicine. 2019; 19: 289–298.

[309] Duan D. Considerations on preclinical neuromuscular disease gene therapy studies (pp. 291–326). In Muscle Gene Therapy, Duan D, Mendell J (eds.) Switzerland: Springer. 2019.